|   ADENOSINE 5'-DIPHOSPHATE MONOPOTASSIUM SALT structure | Common Name | ADENOSINE 5'-DIPHOSPHATE MONOPOTASSIUM SALT | ||
|---|---|---|---|---|
| CAS Number | 72696-48-1 | Molecular Weight | 501.322 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C10H18KN5O12P2 | Melting Point | N/A | |
| MSDS | USA | Flash Point | N/A | |
| Name | Adenosine 5'-diphosphate monopotassium salt dihydrate | 
|---|---|
| Synonym | More Synonyms | 
| Molecular Formula | C10H18KN5O12P2 | 
|---|---|
| Molecular Weight | 501.322 | 
| Exact Mass | 501.006439 | 
| PSA | 273.51000 | 
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter | 
|---|---|
| Hazard Codes | Xi | 
| Safety Phrases | S22-S24/25 | 
| RIDADR | NONH for all modes of transport | 
| Release, neuronal effects and removal of extracellular β-nicotinamide adenine dinucleotide (β-NAD⁺) in the rat brain. Eur. J. Neurosci. 35 , 423-35, (2012) Recent evidence supports an emerging role of β-nicotinamide adenine dinucleotide (β-NAD(+) ) as a novel neurotransmitter and neuromodulator in the peripheral nervous system -β-NAD(+) is released in ne... | |
| Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients. Am. J. Cardiovasc. Drugs 12 , 83-91, (2012) Antithrombotic therapy is imperative in the management of patients presenting with an acute coronary syndrome (ACS). The combination of antiplatelet therapy in conjunction with antithrombotic therapy ... | 
| MFCD00066472 | 
| adenosine 5'-diphosphate monopotassium salt | 
| Potassium 5'-O-{hydroxy[(hydroxyphosphinato)oxy]phosphoryl}adenosine hydrate (1:1:2) | 
| EINECS 274-533-4 | 
| Adenosine, 5'-(trihydrogen diphosphate), potassium salt, hydrate (1:1:2) |